Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

A new malaria study using a very large analysis of pooled individual patient data (IPD) from more than 70,000 patients of all ages, has been published in BMC Medicine by the WorldWide Antimalarial Resistance Network Falciparum Haematology Study Group

Drawing of the earth with representations of locations and interactions © Flickr, Cristhian Alama, Red Mundial

Artemisinin-based combination therapy is the first-line antimalarial treatment for uncomplicated falciparum malaria in most endemic countries but can suppress the bone marrow response and also contribute to haemolysis.

This individual patient data pooled analysis quantifies the underlying haematological response following P. falciparum infection to better understand the comparative benefits and risks of different antimalarial treatments.

The publication 'Haematological consequences of acute uncomplicated falciparum malaria: a WorldWide Antimalarial Resistance Network pooled analysis of individual patient data', involved data from 70,226 patients, from 200 studies conducted between 1991 and 2013, with 72.4% enrolled in Africa, 26.3% in Asia and 1.3% in South America.

The paper determined the main factors associated with haematological fall and recovery following uncomplicated malaria and its treatment. The study highlights patients at greatest risk of severe anaemia who would warrant closer follow up and also whether some treatment regimens offer advantages over others with regard to fast recovery and prevention of anaemia.

WWARN researchers highlighted five main findings:

  • A haemoglobin of <7 g/dL is present in 8.4% of people from Africa, 3.3% of people from Asia-Pacific and 0.1% of people from South America
  • The majority of patients with uncomplicated falciparum malaria have a modest fall in haemoglobin following treatment before subsequently improving with recovery
  • Young children are at a particularly high risk of developing malarial anaemia
  • The risk of anaemia during recovery is exacerbated with a slower parasite clearance
  • In Asia, people treated with an artemisinin-based regimen are at a greater risk of anaemia during recovery compared with those treated with a non-artemisinin-based regimen.

Read the publication 'Haematological consequences of acute uncomplicated falciparum malaria: a WorldWide Antimalarial Resistance Network pooled analysis of individual patient data' on the BMC Medicine website

The full story is available on the WWARN website

Similar stories

Indian authorities sign an MoU for a data and skill-sharing partnership between ICMR and IDDO

The Indian government’s Union Cabinet, chaired by Prime Minister Shri Narendra Modi, has approved a Memorandum of Understanding (MoU) between the Indian Council of Medical Research (ICMR) and the Infectious Diseases Data Observatory (IDDO), based at the University of Oxford.

The GRAM Project has moved

The Global Research on Antimicrobial Resistance (GRAM) Project has a new centre of operations at the University of Oxford, after moving this month from the Big Data Institute to the Centre for Tropical Medicine and Global Health, under the leadership of Dr. Benn Sartorius (PI) and Prof. Christiane Dolecek (co-PI).

Sharing expertise with scientific collaborators in India

The Indian Council for Medical Research (ICMR) National Institute of Malaria Research (NIMR) and IDDO collaborate on a joint capacity building venture to train young researchers across three infectious diseases: malaria, visceral leishmaniasis and lymphatic filariasis

Artemisinin combination therapy trials need longer follow-up to detect late treatment failures for Plasmodium falciparum malaria

WWARN researchers have been assessing the recommended minimum follow-up period in capturing polymerase chain reaction (PCR)-confirmed recrudescence following treatment with fixed-dose artemisinin combination therapies (ACTs) for patients with uncomplicated Plasmodium falciparum malaria.

Paxlovid to be investigated by the RECOVERY Trial as a potential treatment for patients hospitalised with COVID-19

The RECOVERY Trial begins testing the antiviral treatment Paxlovid. Paxlovid, an oral antiviral treatment developed by Pfizer, is a combination of nirmatrelvir and ritonavir. Nirmatrelvir inhibits an enzyme that is critical for the replication of the virus that causes COVID-19, whilst ritonavir increases the concentration of nirmatrelvir.

The RECOVERY Trial - two years on

One trial. Over 47,000 participants. Nearly 200 hospital sites, across six countries. Ten results. Four effective COVID-19 treatments. And behind them all, an army of countless researchers, doctors, nurses, statisticians and supporting staff.